Nordea Investment Management AB Increases Position in Hologic, Inc. (NASDAQ:HOLX)

Nordea Investment Management AB increased its position in Hologic, Inc. (NASDAQ:HOLX) by 32.7% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,213,607 shares of the medical equipment provider’s stock after acquiring an additional 544,889 shares during the period. Nordea Investment Management AB owned approximately 0.98% of Hologic worth $159,911,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Prentiss Smith & Co. Inc. lifted its holdings in shares of Hologic by 0.3% during the third quarter. Prentiss Smith & Co. Inc. now owns 48,696 shares of the medical equipment provider’s stock worth $3,967,000 after purchasing an additional 130 shares during the period. Covestor Ltd increased its stake in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock worth $56,000 after acquiring an additional 133 shares during the period. First Horizon Advisors Inc. raised its holdings in shares of Hologic by 38.3% during the third quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after purchasing an additional 134 shares during the last quarter. Empirical Finance LLC lifted its position in Hologic by 1.8% during the third quarter. Empirical Finance LLC now owns 8,473 shares of the medical equipment provider’s stock valued at $690,000 after purchasing an additional 147 shares during the period. Finally, Wedmont Private Capital boosted its holdings in Hologic by 3.7% in the third quarter. Wedmont Private Capital now owns 4,519 shares of the medical equipment provider’s stock valued at $361,000 after purchasing an additional 162 shares during the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Hologic Trading Up 0.8 %

Shares of Hologic stock opened at $73.77 on Tuesday. Hologic, Inc. has a 1-year low of $70.36 and a 1-year high of $84.67. The company has a debt-to-equity ratio of 0.49, a current ratio of 3.69 and a quick ratio of 3.03. The stock has a market cap of $16.74 billion, a P/E ratio of 22.15, a P/E/G ratio of 2.32 and a beta of 0.97. The stock’s 50 day simple moving average is $76.59 and its 200-day simple moving average is $78.55.

Hologic (NASDAQ:HOLX) last announced its quarterly earnings results on Monday, November 4th. The medical equipment provider reported $1.01 earnings per share for the quarter, meeting the consensus estimate of $1.01. Hologic had a net margin of 19.59% and a return on equity of 19.79%. The firm had revenue of $987.90 million for the quarter, compared to analysts’ expectations of $978.25 million. During the same quarter in the previous year, the company posted $0.89 EPS. The company’s revenue was up 4.5% compared to the same quarter last year. Analysts predict that Hologic, Inc. will post 4.28 EPS for the current fiscal year.

Insider Activity at Hologic

In related news, COO Essex D. Mitchell sold 24,856 shares of the business’s stock in a transaction dated Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the sale, the chief operating officer now directly owns 27,957 shares in the company, valued at approximately $2,134,237.38. The trade was a 47.06 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 1.75% of the stock is currently owned by insiders.

Analyst Upgrades and Downgrades

HOLX has been the topic of a number of recent research reports. StockNews.com upgraded Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. JPMorgan Chase & Co. raised their price objective on shares of Hologic from $92.00 to $94.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 5th. Mizuho decreased their target price on shares of Hologic from $90.00 to $87.00 and set an “outperform” rating for the company in a research note on Tuesday, November 5th. UBS Group raised their price target on shares of Hologic from $84.00 to $90.00 and gave the company a “neutral” rating in a research report on Tuesday, November 5th. Finally, Leerink Partners cut their price objective on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. Six research analysts have rated the stock with a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Hologic currently has an average rating of “Moderate Buy” and a consensus target price of $89.50.

Hologic Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.